Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11041084 | 0.82 | POLB (0.44) | MEN1KMT2AALDH1A1GAALMNA | |
| SCHEMBL9489348 | 0.81 | FFAR1 (0.56) | CA2ALDH1A1FFAR1NR1H4 | |
| SCHEMBL11376149 | 0.81 | MEN1 (0.49) | CA2CAMK2AMEN1KMT2AALDH1A1 | |
| SCHEMBL9825759 | 0.79 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1GAALMNA | |
| SCHEMBL2289168 | 0.79 | CYP4F2 (0.56) | MEN1KMT2AALDH1A1GAALMNA | |
| SCHEMBL30489981 | 0.78 | SELP (0.52) | ALDH1A1AKR1B1GAALMNATSHR | |
| SCHEMBL13222535 | 0.78 | SMN1; SMN2 (0.56) | ALDH1A1FFAR1LMNATSHRNR1H4 | |
| SCHEMBL13972907 | 0.78 | SELP (0.52) | ALDH1A1AKR1B1GAALMNATSHR | |
| SCHEMBL69614 | 0.78 | CA2 (0.79) | CA2CAMK2AMEN1KMT2AALDH1A1 | |
| SCHEMBL14852040 | 0.77 | CA2 (0.58) | CA2CAMK2AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2021-01-28 | — | — | US | disclosed |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2020-05-28 | — | — | US | disclosed |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-10-03 | — | — | US | disclosed |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190047984-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-02-14 | — | — | US | disclosed |
| EP-3210981-B1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA 2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE RESPIRATORY CO LLC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10138220-B1 | Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2018-11-27 | — | — | US | disclosed |
| US-9975875-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2010123766-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-6835724-B2 | Topical antiinflammatory agents for treating inflammatory dermatoses | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-28 | — | — | US | disclosed |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-01 | — | — | US | disclosed |
| US-5824670-A | ANTIINFLAMMATORY AGENTS; TREATING DERMATOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-10-20 | — | — | US | disclosed |
| US-5608093-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0708111-A1 | 17-Desoxy corticosteroid-21-esters, a process for their preparation and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-24 | — | — | EP | disclosed |
| EP-0646593-A1 | Corticoid-17,21-dicarboxylic acid ester and corticosteroid-17-carboxylic acid ester-21-carbonic, process for their production and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0640616-A2 | 17-Alkylcarbonate, 21-0-carbonic/carboxylic acid esters of corticosteroids, a method for their production and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CA2 349/4885CAMK2A 1863/4885MEN1 1362/4885 |
| US-10138220-B1 | Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | CA2 234/4885CAMK2A 1472/4885MEN1 1184/4885 |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | CA2 345/4885CAMK2A 1800/4885MEN1 1447/4885 |
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | CA2 4738/4885CAMK2A 364/4885MEN1 3865/4885 |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | NR3C1, HSD3B1, HSD17B7 | CA2 969/4885CAMK2A 3040/4885MEN1 2777/4885 |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CA2 392/4885CAMK2A 1744/4885MEN1 2417/4885 |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | CA2 349/4885CAMK2A 1863/4885MEN1 1362/4885 |
| US-20190047984-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CA2 278/4885CAMK2A 1675/4885MEN1 1266/4885 |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CA2 349/4885CAMK2A 1863/4885MEN1 1362/4885 |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | CA2 324/4885CAMK2A 1700/4885MEN1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.